Company Overview - Prasis is a data-driven clinical research service provider focused on patient-centered approaches, offering comprehensive project management for clinical trials [1] - The company has established a nationwide network of clinical trial institutions, having undertaken over 4,200 SMO projects as of September 2025, with 2,538 active projects [2] - Prasis has served over 960 clinical trial institutions and covered more than 1,300 sites across over 200 cities in China [2] - The company has supported over 420,000 subjects and facilitated the approval of more than 210 new drugs [2] - Since its establishment, Prasis has distributed a total of CNY 46.1455 million in cash dividends to shareholders [2] Industry Trends - The SMO industry is experiencing a concentration of resources towards leading firms, with smaller companies gradually exiting the market [3] - Clinical trial projects are increasingly complex, with large pharmaceutical companies preferring stable, well-networked suppliers capable of managing intricate projects [3] - Regulatory improvements in China's clinical trial system are enhancing compliance and operational standards, favoring systematic and standardized operators [3] Client Structure - Prasis primarily serves multinational pharmaceutical companies, domestic innovative drug firms, and CROs, collaborating with all top 10 global pharmaceutical companies as of 2024 [4][5] Market Demand - In 2025, the number of registered clinical trials in China reached 5,173, a 6.44% increase year-on-year; 76 innovative drugs were approved, marking a 58% increase [5] - China holds approximately 30% of the global pipeline for new drugs, ranking second worldwide [5] - The total value of authorized transactions for innovative drugs exceeded USD 130 billion in 2025, with over 150 transactions recorded [5] Competitive Advantages - Prasis has a strong competitive edge in various therapeutic areas, including hematologic oncology, thoracic oncology, and rare diseases, among others [6] - The company is actively involved in cutting-edge research fields such as CGT, ADC, and therapeutic nuclear drugs [6] Digital Transformation - Prasis is committed to enhancing operational efficiency through digital tools, aiming to upgrade traditional manual processes and improve project execution [7] - The company emphasizes the development and application of digital and intelligent technologies as a key strategic focus [7]
普蕊斯(301257) - 301257普蕊斯投资者关系活动记录表20260327